Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 145 No. 3738 (2015)

Future development of gastrointestinal cancer incidence and mortality rates in Switzerland: a tumour registry- and population-based projection up to 2030

  • Gaëtan-Romain Joliat
  • Dieter Hahnloser
  • Nicolas Demartines
  • Markus Schäfer
DOI
https://doi.org/10.4414/smw.2015.14188
Cite this as:
Swiss Med Wkly. 2015;145:w14188
Published
06.09.2015

Summary

QUESTIONS UNDER STUDY: Since tumour burden consumes substantial healthcare resources, precise cancer incidence estimations are pivotal to define future needs of national healthcare. This study aimed to estimate incidence and mortality rates of oesophageal, gastric, pancreatic, hepatic and colorectal cancers up to 2030 in Switzerland.

METHODS: Swiss Statistics provides national incidences and mortality rates of various cancers, and models of future developments of the Swiss population. Cancer incidences and mortality rates from 1985 to 2009 were analysed to estimate trends and to predict incidence and mortality rates up to 2029. Linear regressions and Joinpoint analyses were performed to estimate the future trends of incidences and mortality rates.

RESULTS: Crude incidences of oesophageal, pancreas, liver and colorectal cancers have steadily increased since 1985, and will continue to increase. Gastric cancer incidence and mortality rates reveal an ongoing decrease. Pancreatic and liver cancer crude mortality rates will keep increasing, whereas colorectal cancer mortality on the contrary will fall. Mortality from oesophageal cancer will plateau or minimally increase. If we consider European population-standardised incidence rates, oesophageal, pancreatic and colorectal cancer incidences are steady. Gastric cancers are diminishing and liver cancers will follow an increasing trend. Standardised mortality rates show a diminution for all but liver cancer.

CONCLUSIONS: The oncological burden of gastrointestinal cancer will significantly increase in Switzerland during the next two decades. The crude mortality rates globally show an ongoing increase except for gastric and colorectal cancers. Enlarged healthcare resources to take care of these complex patient groups properly will be needed.

References

  1. United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision. http://esa.un.org/wpp/Excel-Data/population.htm. Accessed 2014.
  2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–74.
  3. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701–6.
  4. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254:311–9.
  5. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790–801.
  6. Swiss Federal Statistical Office. Online data search (STAT-TAB) http://www.bfs.admin.ch/bfs/portal/en/index.html. Accessed 2014.
  7. Joinpoint Regression Program. 4.0.1. Jan 2013; Statistical Research and Applications Branch. National Cancer Institute NCI, USA.
  8. Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol. 2000;53:964–72.
  9. Gatenby PAC, Hainsworth A, Caygill C, Watson A, Winslet M. Projections for oesophageal cancer incidence in England to 2033. Eur J Cancer Prev. 2011;20:283–6.
  10. Amiri M, Janssen F, Kunst AE. The decline in stomach cancer mortality: exploration of future trends in seven European countries. Eur J Epidemiol. 2011;26:23–8.
  11. Flook R, van Zanten SV. Pancreatic cancer in Canada: incidence and mortality trends from 1992 to 2005. Can J Gastroenterol. 2009;23:546–50.
  12. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338–66.
  13. Smith BD, Smith GL, Hurria A, Hortobagyl GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–65.
  14. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792–800.
  15. Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol. 2013;5:521–7.
  16. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21:34–59.
  17. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–59.
  18. O’Lorcain P, Deady S, Comber H. Mortality predictions for colon and anorectal cancer for Ireland, 2003–17. Colorectal Dis. 2006;8:393–401.
  19. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer. 2012;107:1195–1202.
  20. Ribes J, Navarro M, Clèries R, Esteban L, Pareja L, Binefa G, et al. Colorectal cancer mortality in Spain: trends and projections for 1985-2019. Eur J Gastroenterol Hepatol. 2009;21:92–100.
  21. Seifeldin R, Hantsch JJ. The economic burden associated with colon cancer in the United States. Clin Ther. 1999;21:1370–9.
  22. Bezerra-de-Souza DL, Bernal MM, Gómez FJ, Gómez GJ. Predictions and estimations of colorectal cancer mortality, prevalence and incidence in Aragon, Spain, for the period 1998-2022. Rev Esp Enferm Dig 2012;104:518–23.
  23. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E. Recent patterns in gastric cancers: A global overview. Int J Cancer. 2009;125:666–73.
  24. Malvezzi M, Bertuccio P, Levi F, La Vecchia. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.
  25. Fernandez E, La Vecchia C, Gonzalez JR, Lucchini F, Negri E, Levi F. Converging patterns of colorectal cancer mortality in Europe. Eur J Cancer. 2005;41:430–7.
  26. Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013;24:2657–71.

Most read articles by the same author(s)